International law firm Freshfields Bruckhaus Deringer has advised Shionogi & Co., Ltd., a major research-driven Japanese pharmaceutical company listed on the Tokyo and Osaka Stock Exchanges, on its S$218 million acquisition of a 66% stake in C&O Pharmaceutical Technology (Holdings) Limited (C&O), a China-based pharmaceutical manufacturer and distributor listed on the Singapore Stock Exchange.
“This is a strategic move for Shionogi to enter into new markets in China through C&O’s established distribution network. We were pleased to have been able to help the Shionogi team navigating the complex multi-jurisdictional framework and work closely with Nomura Securities in the process,” commented Alan Wang, partner in Freshfields’ Shanghai office.
“Congratulations to Shionogi on this groundbreaking deal. It is a milestone for a Japanese company to acquire a controlling stake in a Chinese company listed on a foreign exchange and we expect many other Japanese companies will follow Shionogi’s lead,” explained Junzaburo Kiuchi, partner in Freshfields’ Tokyo office.
The Freshfields team was led by Alan Wang and Junzaburo Kiuchi, together with associates, Shogo Osaka and Oak Ma.
Related Posts:
- None Found